Agree. MTX will have a far bigger market to BTM. Consider all the diabetic ulcers plus infected wounds, necrotising fasceiitis , pilonoidal sinus ops as well as trauma and arterial and venous ulcers. I was impressed with the number of hospitals using our product, nearly 550 and more added to day to get close to 600. EU is a bit of a laggard but should catch up with the US with time and the EU population is 700m
Ann: NovoSorb MTX First Sales and March 2023 $6m Revenue, page-33
-
- There are more pages in this discussion • 148 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.40 |
Change
0.080(3.45%) |
Mkt cap ! $1.660B | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.45 | $2.38 | $2.062M | 854.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 28383 | $2.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.41 | 31503 | 37 |
View Market Depth
| Last trade - 15.22pm 09/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |